In the world of autoimmune diagnostics, time and accuracy are everything. Traditional serological testing often involves multiple assays, manual steps, and long turnaround times. AliveDx is changing that with the MosaiQ® AiPlex CTDplus, a fully automated multiplex microarray immunoassay designed to detect 15 autoantibodies in a single run.
Why multiplex matters in autoimmune diagnostics
Autoimmune connective tissue diseases (CTDs) like lupus, scleroderma, and Sjögren’s syndrome require broad serological profiling. The MosaiQ AiPlex® CTDplus platform simultaneously detects key autoantibodies including:
This eliminates the need for sequential testing, may also help identify common comorbidities within connective tissue diseases, and reduces lab workload.
Study highlights reveal a performance you can trust[1]
In a reference lab in Southern France, 3,258 serum samples (572 reactive, 2,686 non-reactive) were tested using MosaiQ AiPlex® CTDplus and compared to established methods like bead-based immunoassays, IFA, and chemiluminescence.
[1] data on file
Key results:
Overall agreement:
Top performers:
Efficiency meets accuracy
The MosaiQ AiPlex® CTDplus platform offers:
Transform clinical lab workflows
For labs and clinicians this innovation has the potential for optimized diagnostic throughput through:
AliveDx: leaders in the future of autoimmune diagnostics
AliveDx is committed to advancing in-vitro diagnostics through automation, multiplexing, and clinical insights. The MosaiQ AiPlex® CTDplus platform is a leap forward in how autoimmune diseases are tested, bringing clarity, speed and confidence to every test.
*Certain assays and intended uses for the MosaiQ® system are currently under development and are not yet cleared by the U.S. Food and Drug Administration. The MosaiQ® instrument is available in the U.S. as a class II 510(k) exempt device.
©2025 – AliveDx Suisse SA – AliveDx, AliveDx logo, MosaiQ, AiPlex and MosaiQ AiPlex are trademarks or registered trademarks of AliveDx group companies in various jurisdictions. This study was funded by AliveDx Suisse SA, Eysins, Switzerland. Not all methods may be available in all territories. Subject to regulatory clearance in some territories.
